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formally evaluate the validity of the screens with regards
to their ability to correctly identify ADEs. Validity was
expressed as positive predictive value (PPV).
RESULTS: Ten studies published between 1992 and 2000
met the inclusion criteria. Three approaches used to
measure ADE incidence were identiﬁed. Two studies
screened for generic adverse outcomes (e.g., inpatient
deaths), the average PPVs were 1% and 17.4%. Five
studies exclusively screened for surrogate outcomes (anti-
dotes commonly used to treat ADEs, or critical lab values,
such as elevated creatinine or drug levels) to predict the
occurrence of an ADE, with PPVs of 9, 12, 13, 18 and
37%. Three studies tested screens that combined med-
ications and intermediate outcomes (PPVs 12.4, 45 and
53%).
CONCLUSIONS: Automated health care data screens
show promise as ADE incidence measure. Their current
validity, however, does not appear to be sufﬁcient for
cross-sectional comparisons or the evaluation of quality
improvement initiatives. Increasing sophistication of the
screens by including multiple variables that link process
components (e.g. medication) along with adverse out-
comes or surrogates (e.g. lab values, antidotes) appear to
increase screen validity.
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OBJECTIVE: Effectiveness trials are designed to evaluate
patients in their natural setting with fewer constraints
than in efﬁcacy trials. The less-structured environ-
ment can result in a failed trial if participant activity is
unknown. We prepared for this possibility by including
electronic monitoring of medication dosing in a multi-
center trial.
METHODS: The trial was designed to assess the effec-
tiveness of naltrexone for the treatment of chronic 
alcoholism. Patients took either naltrexone or placebo
once daily, using MEMS caps (APREX, Union City, CA)
on their medication bottles to record the date and time
of each opening. We planned analyses by intention-
to-treat and covarying compliance as continuous and cat-
egorical variables (grouped as taking medication during
0–24%, 25–49%, 50–74%, >75% of weeks).
RESULTS: Primary endpoints showed no differences
between treatment groups at 3 months. Electronic moni-
toring revealed that patients took 72 + 31% of naltrex-
one and 70 + 31% of placebo doses (overall compliance
rates). Naltrexone was taken by 13%, 11%, 12%, and
65% of patients by category. Placebo was taken by 14%,
14%, 11%, and 61% of patients by category. Compliance
rates were not signiﬁcantly different overall or by cate-
gory between treatment groups. Planned secondary analy-
ses demonstrated that compliance was a predictor of
success (p = 0.03 for drinks/day), with no interaction for
treatment.
CONCLUSION: These data demonstrate the value of
electronic compliance measurement that provided data on
any period needed for analyses. Without these data, the
results of a complex and expensive study would have been
questioned. Critics could have charged that compliance
rates differed among treatment groups, or that inadequate
amounts of medication were taken to assess outcomes.
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The prognosis for patients with Alzheimer’s disease is
important information for physicians to be able to
provide patients and their relatives as an aid to making
appropriate arrangements before the severe stage is
reached.
OBJECTIVES: To provide prognosis aids for patients
with mild or moderate Alzheimer’s disease based on the
standardised Mini-Mental State Examination (SMMSE).
METHODS: Data from a Canadian cohort study of 206
patients with an initial SMMSE between 10 and 24 were
used to ﬁnd determinants of the three year probability of
reaching a highly dependent stage, deﬁned as SMMSE
<10. The regression equations were also used to derive a
reference failure-time curve. The predicted progression
was compared with that observed in a US study (N =
597).
RESULTS: Proportional hazards analyses showed that at
the mild stage (SMMSE 19 to 24) the presence of hallu-
cinations was associated with a more rapid decline,
whereas at the moderate stage (SMMSE 10 to 18) the
important predictors of decline were a lower baseline
SMMSE score and longer time since onset. Absence of
hallucinations in patients with an SMMSE above 18,
implied a 79% probability of remaining independent after
three years; presence of hallucinations reduced this to
52%, while a prior rate of decline of 2 points/year did so
even further to 43%. Less than half of patients whose
SMMSE was already below 19 and who had symptoms
for ﬁve years or longer remained independent after three
years. An initial score below 14 resulted in a probability
below 30%. The predictions based on the Canadian study
showed reasonable agreement with the progression
observed in the US study.
CONCLUSIONS: These equations permit estimation of
the expected progression of Alzheimer’s disease, and will
